Bayer (OTCMKTS:BAYRY) was upgraded by ValuEngine from a “strong sell” rating to a “sell” rating in a research report issued on Monday, February 4th.
Several other equities research analysts have also recently issued reports on BAYRY. Zacks Investment Research cut shares of Bayer from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 23rd. JPMorgan Chase & Co. cut shares of Bayer from an “overweight” rating to a “neutral” rating in a research note on Wednesday, January 2nd. One analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold”.
Shares of BAYRY traded up $0.32 on Monday, hitting $20.41. 237,631 shares of the stock traded hands, compared to its average volume of 315,899. The company has a market capitalization of $76.11 billion, a P/E ratio of 11.66, a price-to-earnings-growth ratio of 1.29 and a beta of 0.96. The company has a quick ratio of 1.04, a current ratio of 1.59 and a debt-to-equity ratio of 0.80. Bayer has a one year low of $16.58 and a one year high of $32.80.
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Read More: 52-Week High/Low Prices For Stock Selection
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.